205 related articles for article (PubMed ID: 20969638)
1. Editorial Comment to Cancer death from non-muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
Koga F
Int J Urol; 2010 Nov; 17(11):913. PubMed ID: 20969638
[No Abstract] [Full Text] [Related]
2. Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan.
Okajima E; Fujimoto H; Mizutani Y; Kikuchi E; Koga H; Hinotsu S; Shinohara N; Miki T;
Int J Urol; 2010 Nov; 17(11):905-12. PubMed ID: 20969637
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
4. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer.
deVere White RW; Katz MH; Steinberg GD
J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209
[No Abstract] [Full Text] [Related]
5. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
6. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 64 patients.
Montie JE
J Urol; 2005 Jun; 173(6):1920-1. PubMed ID: 15879778
[No Abstract] [Full Text] [Related]
7. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
Tran E; Souhami L; Tanguay S; Rajan R
Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
[TBL] [Abstract][Full Text] [Related]
8. Organ conservation in deeply invasive bladder cancer.
Fair WR
Prog Clin Biol Res; 1991; 370():119-26. PubMed ID: 1924440
[No Abstract] [Full Text] [Related]
9. The prognostic value of the pT-category after combination chemotherapy for patients with invasive bladder cancer who underwent cystectomy. EORTC-GU group.
Splinter TA; Scher HI; Denis L; Bukowski R; Soloway M; Vogelzang N; Klimberg I; Dalesio O; Herr H
Prog Clin Biol Res; 1990; 353():219-24. PubMed ID: 2217422
[No Abstract] [Full Text] [Related]
10. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
[TBL] [Abstract][Full Text] [Related]
11. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer.
Scher HI
J Urol; 1994 Aug; 152(2 Pt 1):574-5. PubMed ID: 8015114
[No Abstract] [Full Text] [Related]
12. Organ preservation in superficial bladder cancer.
Oosterhof GO; Witjes JA; Debruyne FM
Prog Clin Biol Res; 1991; 370():195-202. PubMed ID: 1924451
[No Abstract] [Full Text] [Related]
13. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
de Reijke TM
Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
[No Abstract] [Full Text] [Related]
15. Editorial comment on: Prognostic implications of lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder.
Joudi FN
Eur Urol; 2008 Mar; 53(3):579. PubMed ID: 17804153
[No Abstract] [Full Text] [Related]
16. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
17. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS; Schellhammer PF
J Urol; 2007 Dec; 178(6):2314-30. PubMed ID: 17993339
[No Abstract] [Full Text] [Related]
18. Treatment of high-risk, non-muscle-invasive bladder cancer.
Lerner SP
Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
[No Abstract] [Full Text] [Related]
19. The optimal management of T1G3 bladder cancer.
Emiliozzi P; Pansadoro A; Pansadoro V
BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
[No Abstract] [Full Text] [Related]
20. Treatment delay and prognosis in invasive bladder cancer.
Liedberg F; Anderson H; Månsson W
J Urol; 2005 Nov; 174(5):1777-81; discussion 1781. PubMed ID: 16217282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
